ReviewCHEST pulmonary2026
The Role of Pharmacotherapy for Excessive Daytime Sleepiness in OSA: A Changing Landscape?
Review in CHEST pulmonary, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Topic Importance: Excessive daytime sleepiness is a key presenting feature of patients with OSA. When sleepiness remains despite traditional therapies like CPAP, wakefulness-promoting medication may be appropriate. Treating daytime sleepiness directly also may benefit patients who are unable to tolerate CPAP or other mechanical therapies. The growing number of patients with obesity-related OSA may experience sleepiness caused by both OSA and obesity, and weight loss pharmacotherapy may reduce daytime sleepiness. Review Findings: Several wakefulness promoters are available globally for the indication of residual excessive daytime sleepiness (EDS) in OSA despite CPAP, with some differences in drug access among countries. Recent network meta-analyses have examined the comparative effectiveness of approaches to treat residual EDS in OSA, but clinical guidelines have not been updated since 2013. This review explores the latest evidence on currently available wakefulness promoters and their comparative effectiveness in EDS despite treatment. Evidence for treating sleepiness in the lesser-studied group of patients who are unable to tolerate mechanical therapies for OSA is presented, and the future directions of 2 emerging drug classes are explored, including orexin-2 receptor agonists, with their direct wake-promoting effect, and incretin-based antiobesity agents used in OSA. Summary: We found that existing medications reduce daytime sleepiness in both patients with EDS despite treatment and in patients with OSA who are not using mechanical therapy, but their effectiveness is limited. Further research is required to determine if newly developed orexin-2 receptor agonists and incretin-based obesity medications could change the clinical landscape to treat sleepiness in OSA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.